Infliximab
Measuring Infliximab drug concentrations in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Infliximab allows for reliable measurement of Infliximab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Infliximab immediately before the next administration.
About Using Reagent
-
Sample Types
plasma, serum, and whole blood -
Reaction Time
10mins -
Detection Range
0.2~50 μg/mL -
Intended Use
Quantitative determination of free infliximab in human whole blood/serum/plasma
In Your Medical Field
AFIAS Infliximab measures Infliximab drug levels in patients' blood, using whole blood, serum, or plasma samples. This allows clinicians to obtain TDM results within just 10 minutes. It provides valuable insights into patients’ response to the treatment of Infliximab.